CURLF Curaleaf Holdings, Inc.

OTC
$7.76

Curaleaf Faces a Credibility Test as Street Braces for a Return to Losses

Curaleaf heads into its September-quarter report with an awkward contradiction hanging over it. Last quarter the cannabis operator posted a profit of $0.05 per share, yet Wall Street is now bracing for a loss of $0.16 per share, a swing that would be far worse than the $0.06 loss recorded in the same quarter a year ago. That consensus implies a roughly 167% year-over-year deterioration in per-share results. Put simply, analysts are not treating last quarter's black ink as a new baseline, and the report due after the close on November 3 should show whether that skepticism is warranted or overdone.

The top line offers a firmer footing. Curaleaf generated $340.1 million in revenue last quarter, comfortably ahead of the $320.2 million it booked in the September quarter of 2025. With no published revenue consensus and no formal guidance on the table, the most useful yardstick is that year-ago figure. Revenue holding near the $340 million level would suggest the business has kept the growth it showed in the prior period, while a slide back toward $320 million would imply that last quarter's strength was more fleeting than it looked. In a cannabis market where price compression has been a persistent theme across the industry, sales stability matters as much as outright growth.

The bigger puzzle is the gap between revenue and earnings expectations. If sales are roughly steady but the bottom line is forecast to swing deeply negative, the Street is effectively betting that something below the revenue line, whether gross margin, operating costs, interest expense or other items, weighs heavily on results. That makes margin and expense disclosure the most important part of this release. Evidence that gross margin held up and operating expenses stayed contained would challenge the bearish consensus and lend credibility to the idea that last quarter's profit reflected real progress. Conversely, a loss in line with or worse than $0.16 alongside flat sales would confirm that the company's earnings power remains fragile and that the prior quarter was the exception rather than the trend.

Sentiment has collapsed going into the print. Positioning that read as uniformly bullish ahead of the previous report has faded to only marginally positive, a dramatic cooling that mirrors the stock's behavior. Shares have fallen 10.9% since the last report, trailing the S&P 500 by nearly 9 percentage points. At $7.88, the stock sits much closer to its post-earnings low of $7.31 than its high of $11.98, having given back a large share of the rally that carried it from about $3 to above $10 during the prior quarter. It still trades well above its 200-day moving average of $5.43, so the longer-term uptrend has not broken, but the near-term momentum has clearly stalled. That combination of soured sentiment and a lowered earnings bar means a modest positive surprise could carry more weight than usual, while a miss against already depressed estimates would be hard to explain away.

Ultimately, this report comes down to one question: was last quarter's profit a signal or a blip? Analysts have voted for blip, and the stock's retreat suggests the market has largely agreed. For the narrative of an improving Curaleaf to survive, the company needs to show revenue holding above year-ago levels and a cost structure that keeps losses meaningfully narrower than the Street expects. Anything less would reinforce the view that the path to consistent profitability remains longer than the prior quarter's results implied.

← Back to CURLF news